06:46:36 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-08-29 Bokslutskommuniké 2023
2023-05-25 Kvartalsrapport 2023-Q3
2023-05-17 Extra Bolagsstämma 2023
2023-02-23 Kvartalsrapport 2023-Q2
2022-11-24 X-dag ordinarie utdelning SELECT B 0.00 SEK
2022-11-23 Årsstämma 2023
2022-11-16 Kvartalsrapport 2023-Q1
2022-08-30 Bokslutskommuniké 2022
2022-05-24 Kvartalsrapport 2022-Q3
2022-02-24 Kvartalsrapport 2022-Q2
2021-11-25 X-dag ordinarie utdelning SELECT B 0.00 SEK
2021-11-24 Årsstämma 2022
2021-11-18 Kvartalsrapport 2022-Q1
2021-08-31 Bokslutskommuniké 2021
2021-05-25 Kvartalsrapport 2021-Q3
2021-02-26 Kvartalsrapport 2021-Q2
2020-11-27 Kvartalsrapport 2021-Q1
2020-11-26 Årsstämma 2021
2020-11-26 X-dag ordinarie utdelning SELECT B 0.00 SEK
2020-08-27 Bokslutskommuniké 2020
2020-05-20 Kvartalsrapport 2020-Q3
2020-02-20 Kvartalsrapport 2020-Q2
2019-11-21 X-dag ordinarie utdelning SELECT B 0.00 SEK
2019-11-20 Årsstämma 2020
2019-11-07 Kvartalsrapport 2020-Q1
2019-08-29 Bokslutskommuniké 2019


IndustriLäkemedel & Handel
SelectImmune Pharma är ett läkemedelsbolag. Bolaget ämnar utveckla läkemedelskandidater med fokus på endogena inflammatoriska medel och bakteriemolekyler. Produkterna är inriktade mot att förstärka immunsystemet och används huvudsakligen för behandling av infektionssjukdomar, samt kronisk inflammation. Bolaget grundades år 2017 och innehar störst verksamhet inom den nordiska marknaden.
2022-06-28 15:34:27

"Immunomodulation therapy offers new molecular strategies to treat urinary tract bacterial infections" - a publication in Nature Reviews Urology summarizes the scientific basis behind SelectImmune's drug development strategy. The review also describes successful examples of innate immunomodulation therapy. 

Butler, D., Ambite, I., et al. Immunomodulation therapy offers new molecular strategies to treat UTI. Nature Reviews Urology (2022). DOI: 10.1038/s41585- 022-00602-4. (https://rdcu.be/cP963)

Innovative solutions are needed for the treatment of bacterial infections and a range of antibacterial molecules have been explored as alternatives to traditional antibiotics. A different approach is to explore the immune response for new ways of making the antibacterial defence more efficient. The immune system has a dual role as protector and cause of disease and new therapies aim to increase the protective effect while inhibiting excessive innate immune responses that cause symptoms and tissue pathology during infection.

The concept of innate immunomodulation therapy has been developed successfully in urinary tract infections based on detailed studies of innate immune activation and disease pathogenesis. Effective, disease-specific, immuno-modulatory strategies have been successfully implemented in experimental models. Inhibiting interferon regulatory factor 7, using small interfering RNA is protective in a murine acute pyelonephritis model. In acute cystitis, targeting overactive immune effector molecules such as IL- 1β, MMP-7 and the pain-sensing receptor NK1R are successful in vivo.

The IL-1 receptor antagonist (IL-1RA, anakinra) is now being developed for patients with severe bladder pain syndrome and studies in patients with

recurrent acute cystitis are ongoing. Off label treatment reduced bladder pain, increased the quality of life and allowed responding patients to return to a more normal lifestyle. At the molecular level, treatment inhibited destructive neuro-inflammation, and pain sensing was lowered.

The review summarizes the molecular basis of the excessive innate immune responses that cause symptoms and pathology during urinary tract infections. The review also describes successful examples of innate immunomodulation therapy, making it a realistic option for treating these conditions.

"We are proud to be invited by Nature Reviews Urology to summarize this topic. The Nature Reviews are highly prestigious, with a broad readership," says Ines Ambite, research scientist at Lund University and R&D coordinator, SelectImmune Pharma.

"The potential of immunotherapy is considerable and there is a great need for alternatives to conventional antibacterial therapy," says Catharina Svanborg, Professor and Founder of SelectImmune Pharma